… This review summarizes how these initial genetic findings enabled targeting therapies for
α-synuclein (SNCA), glucocerebrosidase (GBA), and leucine-rich repeat kinase (LRRK2), as …

… In this review, we summarize PD-related mechanisms that can serve as targets of
therapeutic interventions aiming to slow or modify disease progression, as well as previous and …

… key role in the pathogenesis of Parkinson's disease (PD) and … to identify specific mechanisms
and targets involved in the … GD, for development of targeted therapies in synucleinopathies. …

… disease-modifying therapies renders utmost importance. Treatment approaches targeting the
… are promising, urging large clinical trials to open up avenues into targeted therapies in PD. …

… Therapies under evaluation for disease modification Potential therapeutic targets for
Parkinson's disease modification can be broadly considered under categories directly targeting α-…

… Parkinson's disease dementia (PDD) has become an increasing area of research as
treatments for the motor features of Parkinson's disease … be more effectively targeted to specific …

… to develop disease⁃ modifying therapies. The development of targeted drugs blocking …
This review summarizes the recent advances in targeted therapies based on three genetic …

… This review focuses on the role of TNF α in the progress of Parkinson's disease and its
potential as a target for providing novel therapeutic strategies for Parkinson's disease. …

Kinase activating missense mutations in leucine-rich repeat kinase 2 (LRRK2) are
pathogenically linked to neurodegenerative Parkinson’s disease (PD). Over the past decade, …

… The impact of a decreased LRRK2 activity on the immune system will therefore be a major
aspect to consider in LRRK2-targeted therapy. Another issue to consider is the interaction of …